Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 14 | 2025 | 61 | 4.790 |
Why?
|
| Students, Pharmacy | 11 | 2025 | 75 | 3.540 |
Why?
|
| Anticoagulants | 7 | 2025 | 597 | 1.850 |
Why?
|
| Pharmacy | 5 | 2023 | 18 | 1.510 |
Why?
|
| Emotional Intelligence | 3 | 2024 | 15 | 1.130 |
Why?
|
| Pharmaceutical Services | 3 | 2023 | 35 | 1.070 |
Why?
|
| Analgesics, Opioid | 9 | 2024 | 471 | 1.050 |
Why?
|
| Faculty | 3 | 2023 | 98 | 0.960 |
Why?
|
| Pharmacists | 5 | 2023 | 103 | 0.960 |
Why?
|
| Curriculum | 6 | 2024 | 785 | 0.910 |
Why?
|
| Schools, Pharmacy | 6 | 2023 | 26 | 0.840 |
Why?
|
| Webcasts as Topic | 1 | 2023 | 9 | 0.810 |
Why?
|
| Critical Care | 2 | 2018 | 681 | 0.720 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 274 | 0.680 |
Why?
|
| Hemodynamic Monitoring | 1 | 2021 | 16 | 0.680 |
Why?
|
| Social Desirability | 1 | 2020 | 18 | 0.660 |
Why?
|
| Thrombocytopenia | 2 | 2013 | 222 | 0.660 |
Why?
|
| Preceptorship | 1 | 2020 | 28 | 0.650 |
Why?
|
| Dicarboxylic Acids | 1 | 2020 | 37 | 0.640 |
Why?
|
| Hypnotics and Sedatives | 2 | 2024 | 133 | 0.580 |
Why?
|
| Hypolipidemic Agents | 1 | 2020 | 194 | 0.570 |
Why?
|
| Opioid-Related Disorders | 4 | 2023 | 293 | 0.570 |
Why?
|
| Pyridones | 2 | 2024 | 149 | 0.560 |
Why?
|
| Atrial Fibrillation | 6 | 2025 | 734 | 0.560 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2024 | 777 | 0.550 |
Why?
|
| Pipecolic Acids | 2 | 2019 | 10 | 0.550 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 234 | 0.550 |
Why?
|
| Educational Measurement | 5 | 2025 | 318 | 0.540 |
Why?
|
| Fatty Acids | 1 | 2020 | 377 | 0.540 |
Why?
|
| Stroke Volume | 1 | 2020 | 532 | 0.520 |
Why?
|
| Heart Rate | 1 | 2020 | 580 | 0.500 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 612 | 0.500 |
Why?
|
| Pyrazoles | 2 | 2024 | 359 | 0.500 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 26 | 0.430 |
Why?
|
| Codeine | 1 | 2014 | 22 | 0.430 |
Why?
|
| Humans | 48 | 2025 | 131967 | 0.430 |
Why?
|
| Pharmacy Residencies | 1 | 2013 | 6 | 0.410 |
Why?
|
| Propofol | 1 | 2014 | 48 | 0.410 |
Why?
|
| Dexmedetomidine | 1 | 2014 | 47 | 0.410 |
Why?
|
| beta-Alanine | 1 | 2013 | 7 | 0.400 |
Why?
|
| Cough | 1 | 2014 | 99 | 0.400 |
Why?
|
| Thrombin Time | 1 | 2013 | 4 | 0.400 |
Why?
|
| Morpholines | 1 | 2013 | 68 | 0.390 |
Why?
|
| Thiophenes | 1 | 2013 | 68 | 0.390 |
Why?
|
| Benzimidazoles | 1 | 2013 | 155 | 0.370 |
Why?
|
| Pharmacies | 2 | 2023 | 15 | 0.370 |
Why?
|
| Platelet Factor 4 | 1 | 2012 | 22 | 0.370 |
Why?
|
| Buprenorphine | 2 | 2023 | 107 | 0.350 |
Why?
|
| Respiratory Tract Infections | 1 | 2014 | 293 | 0.350 |
Why?
|
| Leadership | 2 | 2024 | 244 | 0.330 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 501 | 0.330 |
Why?
|
| Heparin | 1 | 2012 | 206 | 0.330 |
Why?
|
| Antibodies | 1 | 2012 | 358 | 0.330 |
Why?
|
| Medication Adherence | 3 | 2025 | 334 | 0.330 |
Why?
|
| Heart-Assist Devices | 1 | 2019 | 999 | 0.330 |
Why?
|
| Factor Xa Inhibitors | 2 | 2024 | 59 | 0.310 |
Why?
|
| Rivaroxaban | 2 | 2024 | 48 | 0.310 |
Why?
|
| Problem-Based Learning | 2 | 2023 | 82 | 0.310 |
Why?
|
| Faculty, Pharmacy | 2 | 2020 | 10 | 0.290 |
Why?
|
| Fellowships and Scholarships | 2 | 2023 | 324 | 0.290 |
Why?
|
| Hydrocodone | 2 | 2019 | 36 | 0.270 |
Why?
|
| Intensive Care Units | 3 | 2018 | 519 | 0.260 |
Why?
|
| Drug Monitoring | 2 | 2024 | 286 | 0.250 |
Why?
|
| Chronic Pain | 2 | 2019 | 164 | 0.250 |
Why?
|
| Heart Failure | 1 | 2020 | 2315 | 0.250 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 1215 | 0.240 |
Why?
|
| Prescription Drug Misuse | 2 | 2023 | 8 | 0.240 |
Why?
|
| United States | 11 | 2025 | 11827 | 0.240 |
Why?
|
| Patient Discharge | 3 | 2024 | 512 | 0.230 |
Why?
|
| School Admission Criteria | 3 | 2023 | 29 | 0.230 |
Why?
|
| Empathy | 1 | 2025 | 68 | 0.230 |
Why?
|
| Medically Underserved Area | 1 | 2025 | 88 | 0.220 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 1173 | 0.220 |
Why?
|
| Academic Performance | 1 | 2024 | 25 | 0.220 |
Why?
|
| Sulfonamides | 2 | 2019 | 296 | 0.210 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 103 | 0.210 |
Why?
|
| Markov Chains | 1 | 2024 | 100 | 0.210 |
Why?
|
| Stroke | 3 | 2025 | 1049 | 0.210 |
Why?
|
| Arginine | 2 | 2019 | 344 | 0.210 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 126 | 0.210 |
Why?
|
| Life Change Events | 2 | 2023 | 63 | 0.210 |
Why?
|
| Community Pharmacy Services | 1 | 2023 | 10 | 0.200 |
Why?
|
| Mentoring | 1 | 2024 | 80 | 0.190 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 741 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 544 | 0.180 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 16 | 0.170 |
Why?
|
| Physicians | 3 | 2023 | 634 | 0.170 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2022 | 76 | 0.170 |
Why?
|
| Controlled Substances | 2 | 2019 | 11 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 76 | 0.160 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 4058 | 0.160 |
Why?
|
| Medicare Part C | 3 | 2025 | 35 | 0.160 |
Why?
|
| Male | 16 | 2025 | 65357 | 0.150 |
Why?
|
| Acute Pain | 1 | 2019 | 18 | 0.150 |
Why?
|
| Prescription Drugs | 1 | 2020 | 52 | 0.150 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 121 | 0.150 |
Why?
|
| Primary Prevention | 1 | 2020 | 175 | 0.150 |
Why?
|
| Aspirin | 1 | 2020 | 216 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 371 | 0.140 |
Why?
|
| Minority Groups | 1 | 2020 | 256 | 0.140 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 22 | 0.140 |
Why?
|
| Aged | 9 | 2025 | 21279 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 6922 | 0.140 |
Why?
|
| Retrospective Studies | 9 | 2025 | 17703 | 0.140 |
Why?
|
| Warfarin | 1 | 2019 | 123 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 1255 | 0.140 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 3843 | 0.140 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 174 | 0.130 |
Why?
|
| Pandemics | 2 | 2023 | 1165 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2024 | 810 | 0.130 |
Why?
|
| Adult | 12 | 2025 | 31734 | 0.130 |
Why?
|
| Drug Prescriptions | 3 | 2024 | 230 | 0.130 |
Why?
|
| Female | 15 | 2025 | 71316 | 0.130 |
Why?
|
| Online Systems | 1 | 2016 | 17 | 0.130 |
Why?
|
| Hemodynamics | 1 | 2021 | 819 | 0.130 |
Why?
|
| Administration, Oral | 3 | 2025 | 710 | 0.130 |
Why?
|
| Interviews as Topic | 1 | 2018 | 442 | 0.120 |
Why?
|
| Middle Aged | 10 | 2024 | 28911 | 0.120 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 169 | 0.120 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2020 | 293 | 0.120 |
Why?
|
| Pulmonary Embolism | 2 | 2019 | 191 | 0.110 |
Why?
|
| Enoxaparin | 1 | 2015 | 43 | 0.110 |
Why?
|
| Texas | 5 | 2023 | 3629 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2025 | 13011 | 0.110 |
Why?
|
| Health Personnel | 1 | 2019 | 550 | 0.110 |
Why?
|
| Infusions, Parenteral | 1 | 2014 | 78 | 0.110 |
Why?
|
| Specialization | 1 | 2014 | 75 | 0.100 |
Why?
|
| Internet | 1 | 2016 | 423 | 0.100 |
Why?
|
| Dabigatran | 1 | 2013 | 26 | 0.100 |
Why?
|
| Personnel Selection | 1 | 2014 | 79 | 0.100 |
Why?
|
| Delirium | 1 | 2014 | 66 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 372 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2020 | 946 | 0.090 |
Why?
|
| Opiate Substitution Treatment | 2 | 2023 | 39 | 0.090 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 233 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2014 | 303 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 180 | 0.080 |
Why?
|
| Universities | 2 | 2022 | 122 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 792 | 0.080 |
Why?
|
| Hospitalization | 2 | 2019 | 1942 | 0.080 |
Why?
|
| Students | 2 | 2023 | 251 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2025 | 499 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2014 | 1076 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2013 | 383 | 0.070 |
Why?
|
| Drug and Narcotic Control | 2 | 2019 | 16 | 0.070 |
Why?
|
| Length of Stay | 1 | 2014 | 1400 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 2088 | 0.070 |
Why?
|
| Logistic Models | 2 | 2024 | 1838 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1307 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2015 | 6522 | 0.050 |
Why?
|
| Inappropriate Prescribing | 1 | 2024 | 40 | 0.050 |
Why?
|
| Social Responsibility | 1 | 2024 | 83 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2025 | 152 | 0.050 |
Why?
|
| Risk Factors | 2 | 2020 | 10998 | 0.050 |
Why?
|
| Time Factors | 1 | 2014 | 6285 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2024 | 110 | 0.050 |
Why?
|
| Decision Trees | 1 | 2023 | 57 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 243 | 0.050 |
Why?
|
| Thyroid Gland | 1 | 2023 | 99 | 0.050 |
Why?
|
| Medicare | 1 | 2024 | 440 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3135 | 0.040 |
Why?
|
| College Admission Test | 1 | 2020 | 7 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 206 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2020 | 78 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 838 | 0.040 |
Why?
|
| Refuse Disposal | 1 | 2019 | 5 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2023 | 709 | 0.040 |
Why?
|
| Self Concept | 1 | 2020 | 163 | 0.040 |
Why?
|
| Comorbidity | 1 | 2024 | 1607 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 282 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 280 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 708 | 0.040 |
Why?
|
| Analgesics | 1 | 2019 | 122 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 200 | 0.030 |
Why?
|
| Social Support | 1 | 2020 | 375 | 0.030 |
Why?
|
| Young Adult | 2 | 2024 | 10108 | 0.030 |
Why?
|
| Counseling | 1 | 2019 | 237 | 0.030 |
Why?
|
| United States Government Agencies | 1 | 2016 | 5 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2992 | 0.030 |
Why?
|
| Psychological Theory | 1 | 2016 | 35 | 0.030 |
Why?
|
| Anxiety | 1 | 2023 | 1030 | 0.030 |
Why?
|
| Intention | 1 | 2016 | 100 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 141 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5122 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1626 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 721 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 21008 | 0.020 |
Why?
|